Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3a5aa6f4-7fdd-4087-8b4f-2a9d8eda8727&Preview=1
Date 9/8/2008
Company Name Proteolix
Mailing Address 333 Allerton Avenue South San Francisco, CA 94080
Company Description Proteolix, Inc. is a biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target the proteasome and the control of protein turnover in cells. The company’s focus is on the treatment of cancer, inflammatory disease, and autoimmunity.
Proceeds Purposes Proceeds from the financing will primarily support the completion of the company’s ongoing Phase 2 clinical trials of carfilzomib, and the advancement of this anti-cancer therapeutic into Phase 3 clinical trials for the treatment of multiple myeloma. Proteolix will also use the funds to advance candidates in the company’s earlier stage pipeline of proteasome inhibitors.